Enzyvant
is a biopharmaceutical company that researches and develops novel therapeutics for the treatment of pediatric diseases... Read moreEnzyvant
is a biopharmaceutical company that researches and develops novel therapeutics for the treatment of pediatric diseases... Read more
News
Apr 04, 2023
StreetInsider
Press Release: Enzyvant : Sumitomo Pharma Subsidiary Companies in the U.S., Including Sunovion, to Combine and Form Sumitomo Pharma America
Dec 08, 2022
PMLiVE
Enzyvant: Enzyvant and Altavant announce merger to accelerate rare disease therapies
Apr 25, 2022
The Business Journals
Enzyvant: Biotech to expand Triangle footprint with $34M manufacturing site in Morrisville
Apr 21, 2022
FirstWord Pharma
Enzyvant: Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
Oct 11, 2021
Seeking Alpha
Enzyvant: FDA approves Enzyvant's regenerative tissue-based therapy for pediatric congenital athymia
Oct 09, 2021
StreetInsider
Press Release: Enzyvant : Enzyvant Receives FDA Approval for RETHYMIC (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
Aug 26, 2021
GlobalNewswire
Press Release: Enzyvant : Enzyvant Announces First-Ever Data on Burden of Illness and Costs of Supportive Care for Pediatric Congenital Athymia
Aug 03, 2021
MarketScreener
Enzyvant: Enzyvant Announces Publication of Positive Clinical Data in Pediatric Patients with Congenital Athymia Treated with Investigational RVT-802 (allogeneic processed thymus tissue-agdc)
May 03, 2021
BioSpace
Enzyvant: Aceragen Launches with Acquisition of Enzyvant's Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest
May 03, 2021
FierceBiotech
Enzyvant: Aceragen bags Enzyvant drug and $35M, plots fast path to market
Enzyvant Competitors
1
2
3
4
5
6
7
8
9
10